April 22, 2025CorporateTerumo unveils “Terumo Group Statement on Nature,” a guideline for its actions on conservation and restoration of natural environments
April 16, 2025CorporateTerumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
April 16, 2025CorporateTerumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –
Investors Japanese Financial Results for the Fiscal Year Ended 3/2025 May 14, 2025 Stock Quote Prime Market of TSE: Last Trade JPY Change JPY (%) Volume View Chart Top Management Message Hikaru Samejima Chief Executive Officer GS26: 5-Year Growth strategy 2022 - 2026 IR Library IR materials and various reports Terumo Report Integrated Report 2024 Sustainability Sustainability at the Terumo Group From Devices to Solutions Vision for the Next 10 Years Shareholders & Stock Information on shareholders meeting and stock What's New April 01, 2025 Terumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 117.21 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised February 14, 2025 Audio webcast and Q&A regarding Financial Results for the Third Quarter of FYE 3/2025 February 13, 2025 Presentation regarding Financial Results for the Third Quarter of FYE 3/2025 December 03, 2024 Notice Concerning Status of Acquisition of Own Shares (PDF 88.66 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan) November 08, 2024 Audio webcast and Q&A regarding Financial Results for the Second Quarter of FYE 3/2025 View all Business Overview Introduction to the businesses operated by the Terumo Group /business Technology Introduction to Terumo's research and development activities and production system /technology
April 01, 2025 Terumo announces changes to the names of some businesses within the Cardiac and Vascular Company (PDF 117.21 KB) Disclosure segments of Blood and Cell Technologies Company to also be revised
February 14, 2025 Audio webcast and Q&A regarding Financial Results for the Third Quarter of FYE 3/2025
December 03, 2024 Notice Concerning Status of Acquisition of Own Shares (PDF 88.66 KB) (Acquisition of the Company's own shares under articles of incorporation pursuant to the paragraph 2 of Article 165 of the Companies Act of Japan)
November 08, 2024 Audio webcast and Q&A regarding Financial Results for the Second Quarter of FYE 3/2025
